152 related articles for article (PubMed ID: 1471069)
21. Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin.
Hoppensteadt DA; Gray A; Jeske WP; Walenga JM; Fareed J
Clin Appl Thromb Hemost; 2014 Sep; 20(6):621-8. PubMed ID: 23482722
[TBL] [Abstract][Full Text] [Related]
22. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
23. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
[TBL] [Abstract][Full Text] [Related]
24. Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.
Kalaska B; Sokolowska E; Kaminski K; Szczubialka K; Kramkowski K; Mogielnicki A; Nowakowska M; Buczko W
Eur J Pharmacol; 2012 Jul; 686(1-3):81-9. PubMed ID: 22579410
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of low molecular weight heparin by protamine chloride in vivo.
Harenberg J; Gnasso A; de Vries JX; Zimmermann R; Augustin J
Thromb Res; 1985 Apr; 38(1):11-20. PubMed ID: 4002198
[TBL] [Abstract][Full Text] [Related]
26. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine.
Byun Y; Chang LC; Lee LM; Han IS; Singh VK; Yang VC
ASAIO J; 2000; 46(4):435-9. PubMed ID: 10926141
[TBL] [Abstract][Full Text] [Related]
27. Protamine sulphate inhibits pentasaccharide (SR80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat.
Bernat A; Herbert JM
Haemostasis; 1996; 26(4):195-202. PubMed ID: 8872130
[TBL] [Abstract][Full Text] [Related]
28. Comparative human pharmacology of low molecular weight heparins.
Harenberg J; Stehle G; Augustin J; Zimmermann R
Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
[TBL] [Abstract][Full Text] [Related]
29. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
Mouton C; Calderon J; Janvier G; Vergnes MC
Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
[TBL] [Abstract][Full Text] [Related]
30. Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide.
Kijowski R; Hoppensteadt D; Jeske W; Fareed J
Thromb Res; 1994 Mar; 73(5):349-59. PubMed ID: 8016819
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
Carrie D; Caranobe C; Boneu B
Br J Haematol; 1993 Apr; 83(4):622-6. PubMed ID: 8390849
[TBL] [Abstract][Full Text] [Related]
32. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
33. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
34. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
35. Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics.
Sugiyama T; Itoh M; Ohtawa M; Natsuga T
Thromb Res; 1992 Oct; 68(2):119-29. PubMed ID: 1335615
[TBL] [Abstract][Full Text] [Related]
36. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo characterization of a reversible synthetic heparin analog.
Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
[TBL] [Abstract][Full Text] [Related]
38. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
[TBL] [Abstract][Full Text] [Related]
39. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model.
Thomas DP; Merton RE; Gray E; Barrowcliffe TW
Thromb Haemost; 1989 Apr; 61(2):204-7. PubMed ID: 2546282
[TBL] [Abstract][Full Text] [Related]
40. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
Gatt A; van Veen JJ; Woolley AM; Kitchen S; Cooper P; Makris M
Thromb Haemost; 2008 Aug; 100(2):350-5. PubMed ID: 18690358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
